Pulmonary Arterial Hypertension: Seven-Market Drug Forecast and Market Analysis to 2034

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market through 2034.

The analyst estimated that drug sales for PAH in 2024 were approximately $7.65 billion across the 7MM. With an estimated $5.83 billion in drug sales in 2024, the US dominated the PAH market, contributing 76.3% of the sales in the 7MM. This high market share is primarily due to the large PAH prevalent population and high price of branded drugs in the US compared to the 5EU and Japan. The analyst anticipates that the PAH market will grow to be worth approximately $9.35 billion by 2034, at a compound annual growth rate (CAGR) of 2.0%. The US is expected to maintain its position as the market leader in 2034.

The major drivers of growth in the PAH market during the forecast period include the following:

• The number of total prevalent cases of PAH in the US, France, and the UK is expected to increase during the forecast period in line with population growth, therefore increasing the total addressable patient population. As populations age and diagnostic awareness improves, more patients are being identified and treated for PAH. Expanded screening in high-risk groups and longer patient survival are contributing to a growing prevalence pool, particularly in the US.
• Increased use of combination therapy following the positive outcomes from the AMBITION trial has boosted PAH sales due to higher treatment costs of drug combinations. The AMBITION trial established the superiority of initial dual therapy over monotherapy, prompting widespread adoption of endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitor (PDE5i) combinations. As dual and triple regimens become standard, the use of multiple drugs raises treatment costs and overall market value.
• The increased usage of Merck’s first-in-class Winrevair (sotatercept) and launch of pipeline therapies including Liquidia Corp’s Yutrepia (treprostinil) and Tenax Therapeutics’ imatinib will boost PAH sales. Winrevair is the first approved disease-modifying agent for PAH and is expected to see broad uptake across patient segments. New launches like Yutrepia, with improved inhaled delivery, and oral imatinib, targeting vascular remodeling, will expand treatment options and support continued market growth.
• The major barriers to growth in the PAH market during the forecast period will include the following:
• Low disease awareness among patients and physicians will lead to a lower disease diagnosis rate and delayed diagnosis. Many early PAH symptoms are nonspecific and often misattributed to more common conditions, resulting in under-referral and diagnostic delays. Limited recognition of risk factors and insufficient screening outside of specialist centers continue to hinder timely treatment initiation.

Scope

• Overview of pulmonary arterial hypertension, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized pulmonary arterial hypertension therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the pulmonary arterial hypertension therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for pulmonary arterial hypertension treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global pulmonary arterial hypertension therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM PAH therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PAH therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.